Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATB1651 in mild to moderate onychomycosis
NCT06327295Phase 2Recruiting
- Sponsor
- Amtix Bio
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ATB1651 in onychomycosis (5 arms), sponsored by Amtix Bio. Primary endpoint: Complete Cure Rate up to 252 days. Started Jul 2024; status: recruiting.
02
Drugs
ATB1651
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT06327295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327295.